Opus Genetics, Stock Performance
| IRD Stock | 0.93 0.04 4.12% |
Opus Genetics, has a performance score of 2 on a scale of 0 to 100. The company holds a Beta of 1.55, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Opus Genetics, will likely underperform. Opus Genetics, right now holds a risk of 4.95%. Please check Opus Genetics, kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if Opus Genetics, will be following its historical price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Opus Genetics, are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, Opus Genetics, may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
Last Split Factor 1:4 | Dividend Date 2020-11-06 | Last Split Date 2020-11-06 |
1 | Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | 12/19/2024 |
2 | Acquisition by Magrath George of 6200 shares of Opus Genetics, subject to Rule 16b-3 | 12/23/2024 |
3 | Acquisition by Magrath George of 100000 shares of Opus Genetics, at 0.976 subject to Rule 16b-3 | 12/26/2024 |
4 | Opus Genetics CEO Magrath George buys 97,600 in stock - Investing.com | 12/30/2024 |
5 | Acquisition by Bennett Jean of 34021 shares of Opus Genetics, at 1.23 subject to Rule 16b-3 | 01/02/2025 |
6 | Opus Genetics Enhances Executive Severance Packages - TipRanks | 01/24/2025 |
7 | Disposition of 6751 shares by Hoffmann Bernhard of Opus Genetics, at 1.14 subject to Rule 16b-3 | 02/04/2025 |
8 | Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to ... | 02/07/2025 |
9 | Disposition of 5193 shares by Ashwath Jayagopal of Opus Genetics, at 1.15 subject to Rule 16b-3 | 02/13/2025 |
10 | Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program | 02/18/2025 |
11 | Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic ... | 02/26/2025 |
12 | Opus Genetics In Jan, Got Paragraph IV Certification Notice From Winston Strawn, Counsel To Sandoz Incorporated - Marketscreener.com | 03/04/2025 |
13 | Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology 2025 Meeting | 03/05/2025 |
| Begin Period Cash Flow | 42.6 M |
Opus |
Opus Genetics, Relative Risk vs. Return Landscape
If you would invest 91.00 in Opus Genetics, on December 17, 2024 and sell it today you would earn a total of 2.00 from holding Opus Genetics, or generate 2.2% return on investment over 90 days. Opus Genetics, is generating 0.1551% of daily returns assuming volatility of 4.9508% on return distribution over 90 days investment horizon. In other words, 44% of stocks are less volatile than Opus, and above 97% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Opus Genetics, Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics,'s investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Opus Genetics,, and traders can use it to determine the average amount a Opus Genetics,'s price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0313
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | IRD | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.95 actual daily | 44 56% of assets are more volatile |
Expected Return
| 0.16 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Opus Genetics, is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Opus Genetics, by adding it to a well-diversified portfolio.
Opus Genetics, Fundamentals Growth
Opus Stock prices reflect investors' perceptions of the future prospects and financial health of Opus Genetics,, and Opus Genetics, fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Opus Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (2.07) % | ||||
| Current Valuation | (962.64 K) | ||||
| Shares Outstanding | 31.57 M | ||||
| Price To Book | 1.04 X | ||||
| Price To Sales | 4.26 X | ||||
| Revenue | 19.05 M | ||||
| EBITDA | (29.47 M) | ||||
| Net Income | (9.99 M) | ||||
| Total Debt | 4.04 M | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (1.11 M) | ||||
| Earnings Per Share | (1.09) X | ||||
| Total Asset | 53.95 M | ||||
| Retained Earnings | (81.47 M) | ||||
About Opus Genetics, Performance
By analyzing Opus Genetics,'s fundamental ratios, stakeholders can gain valuable insights into Opus Genetics,'s financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Opus Genetics, has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Opus Genetics, has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Opus Genetics, is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about Opus Genetics, performance evaluation
Checking the ongoing alerts about Opus Genetics, for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Opus Genetics, help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Opus Genetics, has some characteristics of a very speculative penny stock | |
| Opus Genetics, had very high historical volatility over the last 90 days | |
| Opus Genetics, has high likelihood to experience some financial distress in the next 2 years | |
| Opus Genetics, was previously known as OCUP Old and was traded on NASDAQ Exchange under the symbol OCUP. | |
| The company reported the last year's revenue of 19.05 M. Reported Net Loss for the year was (9.99 M) with loss before taxes, overhead, and interest of (15.39 M). | |
| Opus Genetics, generates negative cash flow from operations | |
| Opus Genetics, has a very weak financial position based on the latest SEC disclosures | |
| About 16.0% of the company shares are held by company insiders | |
| Latest headline from globenewswire.com: Opus Genetics Announces Presentations at Association for Research in Vision and Ophthalmology 2025 Meeting |
- Analyzing Opus Genetics,'s financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Opus Genetics,'s stock is overvalued or undervalued compared to its peers.
- Examining Opus Genetics,'s industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Opus Genetics,'s management team can have a significant impact on its success or failure. Reviewing the track record and experience of Opus Genetics,'s management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Opus Genetics,'s stock. These opinions can provide insight into Opus Genetics,'s potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Opus Stock analysis
When running Opus Genetics,'s price analysis, check to measure Opus Genetics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Opus Genetics, is operating at the current time. Most of Opus Genetics,'s value examination focuses on studying past and present price action to predict the probability of Opus Genetics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Opus Genetics,'s price. Additionally, you may evaluate how the addition of Opus Genetics, to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Transaction History View history of all your transactions and understand their impact on performance |